Rockwell Automation and Cytiva Launch Platform to Accelerate Digital Transformation for Biopharma Companies

Why It Matters

By eliminating siloed legacy systems, Figurate accelerates tech transfer and reduces error‑prone manual work, giving biopharma firms a faster path to market and lower operational costs. The platform’s interoperability also positions manufacturers to adopt continuous processing and data‑driven optimization more readily.

Key Takeaways

• Figurate SCADA links Cytiva equipment with Rockwell FactoryTalk.
• Open architecture enables third‑party device integration across bioprocesses.
• Platform scales from R&D to commercial manufacturing without redesign.
• Pre‑engineered templates cut deployment time and validation effort.
• Centralized monitoring improves cGMP compliance and reduces error risk.

Pulse Analysis

The biopharma sector is at a crossroads where increasing product complexity meets mounting pressure for speed and compliance. Traditional control systems, often built as isolated islands, hinder data flow and inflate validation cycles. As manufacturers shift toward continuous processing and real‑time analytics, the need for a unified digital backbone becomes a strategic imperative rather than a technical nicety.

Figurate SCADA directly addresses these pressures by offering an open, modular platform that bridges Cytiva’s specialized bioprocessing instruments with Rockwell’s robust automation suite. Its plug‑and‑play architecture reduces the engineering effort required to integrate new equipment, while pre‑configured templates accelerate commissioning and validation under cGMP guidelines. The result is a tighter feedback loop between process development and commercial scale‑up, enabling faster tech transfer, lower capital spend, and more reliable batch outcomes.

Looking ahead, the adoption of interoperable SCADA solutions like Figurate could reshape competitive dynamics in the life‑sciences supply chain. Companies that embed such platforms early may capture efficiency gains, improve regulatory audit trails, and unlock advanced process‑intensification strategies. As digital twins and AI‑driven optimization become mainstream, a scalable, vendor‑agnostic control layer will be a critical enabler for the next generation of biomanufacturing excellence.